Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study.

ABSTRACT:

Background

Patients with end-stage kidney disease (ESKD) are at significantly increased risk for both thrombosis and bleeding relative to those with normal renal function. The optimal therapy of venous thromboembolism (VTE) in patients with ESKD is unknown.

Objective

To compare the safety and effectiveness of apixaban relative to warfarin in patients with ESKD and acute VTE.

Design, setting and participants

New-user, active-comparator retrospective United States population-based cohort with inverse probability of treatment weighting, using the United States Renal Data System data from 2014 to 2018. We included adults with ESKD on hemodialysis or peritoneal dialysis who were newly initiated on apixaban or warfarin for an acute VTE.

Main outcome and measures

The

SUBMITTER: Ellenbogen MI 

PROVIDER: S-EPMC9804323 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature